|
OVERVIEW
In April of 2008, the US American Academy of Pediatrics expanded the age range for annual influenza immunization
to include all children 6 months to 18 years old. This expansion targets all school-aged children, the population
that bears the greatest disease burden and is at significantly higher risk of needing influenza-related medical care
compared to healthy adults. The reduction of influenza transmission among school-aged children using influenza vaccine
with the subsequent impact on the influenza burden in household contacts and community members is still controversial.
However, studies conducted in Japan and the United States have demonstrated that vaccinating school-aged
children protects the elderly from influenza. With the limited availability of influenza vaccine worldwide, strategies
that could limit the transmission and burden of seasonal and pandemic influenza are needed. Vaccination of
school-aged children could be a feasible, early, and cost-effective strategy to contain the spread of influenza in the
population, limiting its impact amongst highest risk groups.
GOAL
To provide specialists in the field of pediatric infectious disease and leaders in public policy the opportunity to participate in a web archive of the proceedings of a symposium titled Preventing Influenza in School-Aged Children: Evidence-Based Decision Making on Universal Vaccination. This web archive presents the burden of influenza worldwide and provides participants the opportunity to evaluate strategies that could limit the transmission and burden of seasonal and pandemic influenza.
INTENDED AUDIENCE
This activity is designed for specialists in the field of pediatric infectious disease and leaders in public policy who treat and manage school-aged patients with influenza. No prerequisites required.
LEARNING OBJECTIVES
Upon the conclusion of this activity, the participant should be able to:
- ASSESS the burden of influenza on the individual and societal level worldwide.
- IDENTIFY goals and strategies for vaccination policies in response to anticipated influenza outbreaks
- DESCRIBE the importance of vaccinating school aged children to minimize the impact of influenza and decrease the risk for potential epidemics.
The Johns Hopkins University School of Medicine takes
responsibility for the content, quality, and scientific integrity
of this CME activity.
CME INFORMATION
Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement — The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.
The estimated time to complete this activity: 1.5 hours.
Release date: March 31, 2010 Expiration date: March 31, 2012
Activity Format — Archived webcast of a symposium held during the World Society for Pediatric Infectious Diseases’ (WSPID) 6th World Congress.
Full Disclosure Policy Affecting CME Activities — As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Participating Faculty reported the following:
Edwin J. Asturias, MD (Chair)
Associate Professor
Department of International Health
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland
Center for Health Studies
University del Valle de Guatemala
Guatemala City, Guatemala
Dr Asturias reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Sir Roy Anderson FRS, FMedSci
Rector, Imperial College London
Professor
Department of Infectious Disease Epidemiology
Division of Primary Care and Population Health Sciences
Faculty of Medicine, Imperial College
St. Mary’s Medical School
Norfolk Place
London, United Kingdom
Dr. Anderson eports receiving grants/research support from and serving as a non-executive director for GlaxoSmithKline.
Rosanna Lagos, MD
Centro para Vacunas en Desarrollo
Hospital de Ninos Roberto del Rio
Santiago, Chile
Dr Lagos reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Marie-Paule Kieny, PhD
Director, Initiative for Vaccine Research
World Health Organization
Geneva, Switzerland
Dr Kieny reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Shabir A. Madhi, MD, PhD
Professor of Vaccinology
Chair, Department of Science and Technology/National Research Foundation:
Vaccine Preventable Diseases
University of Witwatersrand
Johannesburg, South Africa
Dr Madhi reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Kathleen M. Neuzil, MD, MPH
Director, Influenza Vaccine Project
PATH
Clinical Associate Professor
Departments of Medicine and Global Health
University of Washington
Seattle, Washington
Dr Neuzil reports serving as a principal investigator on financial remuneration or gifts-in-kind from The Bill & Melinda Gates Foundation for the Advancing Pandemic Influenza Vaccines Project, 2007–2011; from the GAVI Alliance for the Accelerated Development and Introduction Plan for Rotavirus Vaccines, 2003–2010; and, from the US CDC for the Senegal Influenza Vaccine Effectiveness Study, 2008–Present.
Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion
The audience is advised that no faculty member in this CME activity references unlabeled or unapproved uses of drugs or devices.
DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. The Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.
AGENDA
Please complete the pre-test, listen to the following presentations, and complete the post-test and evaluation to receive CME credit for this activity.
Pre-Test
Introduction and Conference Goals
Dr. Asturias
Prevention Strategies in School-Aged Children
Sir Roy Anderson
Vaccination of School-Aged Children: The US Perspective
Dr. Neuzil
Perspectives on the Burden of Influenza, Including School-Aged Children
(Panel discussion)
Prevention Strategies in School-Aged Children
Dr. Marie-Paule Kieny
Epidemiology of Influenza Virus Illness in Sub-Saharan South Africa
Dr. Madhi
Influenza Surveillance and Vaccination in Chile
Dr. Lagos
Universal Vaccination: Should it Be the Goal?
(Panel Discussion)
Final Q&A and Concluding Remarks
Dr. Asturias
Post-Test
|
